Back to School: How biopharma can reboot drug development. Access exclusive analysis here
AVE's Aventis Pharma AG unit bought C$5.8 million (US$4 million) of IZP convertible
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury